Browsing Tag
biotechnology acquisition
6 posts
Mural Oncology shareholders to receive fixed $2.035 per share as XOMA Royalty deal nears closing
Mural Oncology confirms a fixed $2.035 per share cash payout as its acquisition by XOMA Royalty nears closing, locking in a definitive exit for investors.
Repare Therapeutics (RPTX) to be acquired by XenoTherapeutics in CVR-backed buyout
Repare Therapeutics to be acquired by XenoTherapeutics with $1.82/share cash payout and long-term CVR upside. Find out what this means for investors.
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive…
Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a…
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc.…
AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio
AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments…